Short answer
LEMAITRE VASCULAR INC (LMAT) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $70M (up 9.6% year over year) with net income of $17M.
Q2 2026 key financials · XBRL
- Revenue
- $70M
- +9.6% YoY · +5.8% QoQ
- Net income
- $17M
- +23.7% YoY · +8.7% QoQ
- Operating margin
- 29.0%
- Gross margin
- 72.1%
- EPS (diluted)
- $0.74
- +23.3% YoY · +8.8% QoQ
Source: XBRL data from the LEMAITRE VASCULAR INC (LMAT) Q2 2026 10-Q on SEC EDGAR. USD.
LEMAITRE VASCULAR INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- FDA re-inspection of Artegraft facility in June 2026 identified additional new observations
- Ongoing FDA warning-letter remediation requiring continued agency engagement and management resources
- Potential enforcement action or approval suspension threatening Artegraft operations and regulatory compliance
- April 2025 catheter packaging recall involving inadequate seals and potentially compromised sterile barriers
- Recall-related costs and customer replacements from TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LEMAITRE VASCULAR INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.